FreeCME

Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer

This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and MedNet.

For more information visit: www.mednetus.net

Grantors:

Lilly US, LLC
Novartis Pharmaceuticals Corporation
Genomic Health

Scroll to the Bottom of this Information to Begin this Course

Target Audience

This webcast is directed primarily to hematologists/oncologists, radiation oncologists, surgical oncologists, pathologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new developments for treatment of lung and breast cancers. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity. 

Statement of Need/Program Overview

This webcast is intended to improve care of patients with lung and breast cancers by accelerating adoption of new guidelines and evidence-based practice change.  In addition to chemotherapy and targeted therapy of lung and breast cancers, this symposium will focus on individualized treatment options. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 6 continuing education activites.

Click the links below to review the activity launch pages containing full disclosure information.

 

Module 1 — 1.5 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select lung cancer patients for personalized chemotherapy based on molecular profiling
  • Outline the importance of optimizing VEGF inhibitors for the treatment of  lung cancer
  • Identify the role of personalized maintenance therapy in lung cancer

 

Module 2 — 1.5 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Update the role of KRAS and PARP inhibitors in the treatment of lung cancer
  • Outline the clinical data supporting the optimal use of EGFR and ALK inhibitors for lung cancer
  • Identify the role of immune checkpoint pathway inhibitors for lung cancer

 

Module 3 — 2.0 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the important cooperative group clinical trials for lung cancer
  • Identify and utilize radiation therapy options for lung cancer
  • Discuss economic value of novel treatments for lung and breast cancer

 

Module 4 — 2.0 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review treatment options for early breast cancer
  • Outline treatment options for HER-2 positive advanced/metastatic breast cancer
  • Indicate the optimal use of m-TOR inhibitors in the treatment of endocrine-sensitive metastatic breast cancer

 

Module 5 — 2.0 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify emerging chemotherapeutic and endocrine agents in treatment of breast cancer
  • Review genetic counseling and management of breast cancer in BRCA carriers
  • Indicate the utility of genomic analysis in identifying subtypes and novel targets for triple negative breast cancer

 

Module 6 — 2.0 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe strategies to treat bone loss in women with breast cancer
  • Identify the role of predictive and prognostic markers for response and survival in patients with breast cancer
  • Describe the current status of radiation therapy in optimizing local control in breast cancer